
1. Technology overview
Cellbyte is a Munich, Germany company in Y Combinator's Winter 2022 batch, listed with founding year 2024; its contact page says it hires in Munich. It sells AI agents and a platform for pharma Pricing and Market Access teams.
The platform answers research questions in plain language over a proprietary clinical, regulatory, HTA and pricing database, with outputs traceable to sources. Expert services are offered alongside.
2. Highlighted features & specifications
- Plain-language research: questions answered over a proprietary database.
- Source traceability: every output traceable.
- Workflow automation: recurring market access workflows.
- Cellbyte 2.0: end-to-end work from question to report, with alerts on new evidence.
- Expert services: life-science experts working with the AI.
3. Potential application
A pharma affiliate in Vietnam could benchmark comparator prices across markets. A distributor could prepare reimbursement dossiers faster.
4. Benefits
The site says 8 of the top 20 pharma companies use it and cites 97% user satisfaction in a July/August 2026 survey. Weeks of manual research become minutes. Outputs are traceable to source.
5. Market trends & opportunities
Pharma pricing and reimbursement research is slow and manual. Vietnamese pharma distributors and local pharma units evaluate drug listing and pricing.
6. Other information
YC W22; also raised $2.75M from Frontline Ventures (own blog, 2025-11-18). Pharma market access focus rather than provider operations.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































